new retatrutide 🎙️ EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Retatrutide Promises Big Weight Loss,

Unique to Medicare, both GLP1s and SGLT2s have gained ground, making up 23% and 17% of the market respectively by mid2025

She used the platform for approximately six months, taking GLP-1 medications, and had lost about 50 pounds by the time she stopped taking them after a bad reaction

That said, combining aerobic exercise (e.g., walking, running, cycling) with strength training (e.g., weightlifting, bodyweight exercises) tends to deliver the best results for weight loss, fat loss , and overall health

This will come as great news for patients who have wanted to try GLP-1 treatments but were needle averse

Further reading: Retatrutide side effects Note: Retatrutide is currently still undergoing clinical trials and has not been approved for use in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA)

BMJ 381 , e074572 (2023)